This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

David Wilks

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Dr David Wilks is a British researcher and infectious diseases specialist, who will soon be retiring from the Regional Infectious Diseases Unit at Western General Hospital, run by NHS Lothian in Scotland, UK.[1] Dr Wilks is an honorary associate of Edinburgh Medical School.[2]

Notable studies[edit | edit source]

PACE trial: Main trial outcome

  • 1999, Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome [4] (Abstract)
  • 2001, Health-related quality of life in patients with chronic fatigue syndrome: an international study[5] (Abstract)
  • 2002, The role of fear of physical movement and activity in chronic fatigue syndrome.[7] (Full text)

Letters[edit | edit source]

PACE trial authors' responses

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. NHS Scotland (2018). "Western General Hospital | Jobs" (PDF). Retrieved February 17, 2019.
  2. "Associate Members & Honorary Staff". The University of Edinburgh. Retrieved February 17, 2019.
  3. White, PD; Goldsmith, KA; Johnson, AL; Potts, L; Walwyn, R; DeCesare, JC; Baber, HL; Burgess, M; Clark, LV; Cox, DL; Bavinton, J; Angus, BJ; Murphy, G; Murphy, M; O'Dowd, H; Wilks, D; McCrone, P; Chalder, T; Sharpe, M; The PACE Trial Management Group (March 5, 2011), "Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial", The Lancet, 377 (9768): 823–836, doi:10.1016/S0140-6736(11)60096-2, PMID 21334061
  4. Myers, C.; Wilks, D. (January 1, 1999). "Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome". Quality of Life Research. 8 (1): 9–16. doi:10.1023/A:1026459027453. ISSN 1573-2649.
  5. Hardt, Jochen; Buchwald, Dedra; Wilks, D; Sharpe, M; Nix, W.A; Egle, U.T (August 2001). "Health-related quality of life in patients with chronic fatigue syndrome". Journal of Psychosomatic Research. 51 (2): 431–434. doi:10.1016/S0022-3999(01)00220-3.
  6. Wilks, David; Sharpe, Michael (August 31, 2002). "Fatigue". BMJ. 325 (7362): 480–483. doi:10.1136/bmj.325.7362.480. ISSN 0959-8138. PMID 12202331.
  7. Silver, A; Haeney, M; Vijayadurai, P; Wilks, D; Pattrick, M; Main, C.J (June 2002). "The role of fear of physical movement and activity in chronic fatigue syndrome". Journal of Psychosomatic Research. 52 (6): 485–493. doi:10.1016/S0022-3999(01)00298-7.
  8. White, PD; Chalder, T; Sharpe, M; Angus, BJ; Baber, HL; Bavinton, J; Burgess, M; Clark, LV; Cox, DL; DeCesare, JC; Goldsmith, KA; Johnson, AL; McCrone, P; Murphy, G; Murphy, M; O'Dowd, H; Potts, L; Walwyn, R; Wilks, D (January 2017). "Response to the editorial by Dr Geraghty". Journal of Health Psychology. 22 (9): 1113–1117. doi:10.1177/1359105316688953.